Related Experiment Video
Updated: Apr 7, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
MVs and MVs-Crocin as Novel Therapeutic Agents for Lung Cancer, Apoptosis, and Gene Regulation
Hosein Keshavaerz1, Bita Zand1, Leila Sadat Nilchiani1
1Department of cellular and molecular Biology, TeMS.C, Islamic Azad University, Tehran Medical Sciences, Tehran, Iran.
Introduction:
Lung cancer is one of the most common malignancies worldwide. Stem cells and their secretions have recently attracted attention as potential therapeutic agents due to their anti-cancer properties. This study investigated the effects of mesenchymal stem cell-derived microvesicles (MVs) and Crocinpreconditioned MVs (MVs-Crocin) on lung cancer cells (A549) compared with normal cells (HEK293).
Materials And Methods:
Mesenchymal stem cells were preconditioned with Crocin, and microvesicles were subsequently isolated. The appropriate therapeutic concentrations of MVs and MVs-Crocin were determined using the MTT assay. A549 and HEK293 cells were treated with the optimized doses. Apoptosis was assessed by flow cytometry, and the expression of apoptotic genes was analyzed through real-time PCR.
Results:
MTT assay results identified 40 μg/ml for MVs and 50 μg/ml for MVs-Crocin as optimal therapeutic concentrations. Treatment with MVs and MVs-Crocin significantly reduced the survival of A549 cells, while apoptosis assays and gene expression analysis confirmed enhanced apoptotic activity in treated cancer cells.
Discussion:
Both MVs and MVs-Crocin demonstrated potent anti-cancer effects by reducing lung cancer cell survival and inducing apoptosis. Preconditioning with Crocin appeared to further strengthen the therapeutic efficacy of MVs. Importantly, these effects were more pronounced in cancer cells compared to normal cells, indicating selective anti-cancer potential.
Conclusion:
MVs and MVs-Crocin promote apoptosis in lung cancer cells and may serve as promising candidates for the development of novel therapeutic strategies against lung cancer.
Insights
Mesenchymal stem cell-derived microvesicles (MVs), especially when preconditioned with Crocin (MVs-Crocin), effectively reduce lung cancer cell survival and induce apoptosis. These findings highlight MVs as promising agents for novel lung cancer therapies.
Area of Science:
- Biotechnology
- Cancer Research
- Cell Biology
Background:
- Lung cancer remains a leading global malignancy.
- Mesenchymal stem cells and their derivatives show potential in cancer therapy.
- This study explores microvesicles (MVs) from stem cells and Crocin-preconditioned MVs (MVs-Crocin) against lung cancer cells.
Purpose of the Study:
- To evaluate the anti-cancer effects of MVs and MVs-Crocin on A549 lung cancer cells.
- To compare the efficacy of MVs and MVs-Crocin against normal HEK293 cells.
- To investigate the mechanism of action, focusing on apoptosis induction.
Main Methods:
- Mesenchymal stem cells were preconditioned with Crocin.
- Microvesicles (MVs) and MVs-Crocin were isolated and their optimal concentrations determined via MTT assay.
- Lung cancer (A549) and normal (HEK293) cells were treated, followed by apoptosis assessment (flow cytometry) and gene expression analysis (real-time PCR).
Main Results:
- Optimal concentrations were identified as 40 μg/ml for MVs and 50 μg/ml for MVs-Crocin.
- Both MVs and MVs-Crocin significantly decreased A549 cell viability.
- Apoptosis assays and gene expression data confirmed increased apoptosis in treated cancer cells.
Conclusions:
- MVs and MVs-Crocin exhibit significant anti-cancer properties against lung cancer cells.
- Crocin preconditioning enhances the therapeutic potential of MVs.
- The observed effects are more pronounced in cancer cells, suggesting selective therapeutic action.
More Related Videos
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
MicroRNAs
MicroRNAs
Drugs that Destabilize Microtubules
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Abnormal Proliferation